| A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1) J Horrigan, TB Gomes, M Snape, N Nikolenko, A McMorn, S Evans, ... Pediatric Neurology 112, 84-93, 2020 | 69 | 2020 |
| Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study E Van Overbeeke, R Janssens, C Whichello, K Schölin Bywall, J Sharpe, ... Frontiers in pharmacology 10, 1395, 2019 | 58 | 2019 |
| GNE myopathy: from clinics and genetics to pathology and research strategies O Pogoryelova, JA González Coraspe, N Nikolenko, H Lochmüller, ... Orphanet journal of rare diseases 13, 1-15, 2018 | 55 | 2018 |
| Disease burden of myotonic dystrophy type 1 E Landfeldt, N Nikolenko, C Jimenez-Moreno, S Cumming, DG Monckton, ... Journal of neurology 266, 998-1006, 2019 | 35 | 2019 |
| Patient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA R Janssens, S Russo, E van Overbeeke, C Whichello, S Harding, J Kübler, ... The Patient-Patient-Centered Outcomes Research 12, 513-526, 2019 | 34 | 2019 |
| Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the UK C linical P ractice R esearch D atalink Y Wang, RM Pfeiffer, R Alsaggaf, W Meeraus, JC Gage, LA Anderson, ... International journal of cancer 142 (6), 1174-1181, 2018 | 34 | 2018 |
| The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research L Wood, I Cordts, A Atalaia, C Marini-Bettolo, P Maddison, M Phillips, ... Journal of neurology 264, 979-988, 2017 | 29 | 2017 |
| Benign and malignant tumors in the UK myotonic dystrophy patient registry R Alsaggaf, Y Wang, C Marini‐Bettolo, L Wood, N Nikolenko, ... Muscle & nerve 57 (2), 316-320, 2018 | 23 | 2018 |
| Analysis of the functional capacity outcome measures for myotonic dystrophy AC Jimenez‐Moreno, N Nikolenko, M Kierkegaard, AP Blain, J Newman, ... Annals of clinical and translational neurology 6 (8), 1487-1497, 2019 | 19 | 2019 |
| Analyzing walking speeds with ankle and wrist worn accelerometers in a cohort with myotonic dystrophy AC Jimenez-Moreno, SJ Charman, N Nikolenko, M Larweh, C Turner, ... Disability and Rehabilitation 41 (24), 2972-2978, 2019 | 18 | 2019 |
| Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA) G DiPaolo, C Jimenez-Moreno, N Nikolenko, A Atalaia, DG Monckton, ... Journal of Neurology 264, 701-708, 2017 | 17 | 2017 |
| Activities of daily living in myotonic dystrophy type 1 E Landfeldt, N Nikolenko, C Jimenez‐Moreno, S Cumming, DG Monckton, ... Acta Neurologica Scandinavica 141 (5), 380-387, 2020 | 11 | 2020 |
| Survival patterns and cancer determinants in families with myotonic dystrophy type 1 AF Best, JE Hilbert, L Wood, WB Martens, N Nikolenko, C Marini‐Bettolo, ... European journal of neurology 26 (1), 58-65, 2019 | 11 | 2019 |
| miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1 D Koutalianos, A Koutsoulidou, C Mytidou, AC Kakouri, A Oulas, ... Molecular Therapy-Methods & Clinical Development 23, 169-183, 2021 | 7 | 2021 |
| Impact of subarachnoid haemorrhage Canadian clinical decision rules for investigation of acute headache: a retrospective case note review A Yiangou, N Nikolenko, J Noreikaite, S Thondam The Lancet 389, S103, 2017 | 7 | 2017 |
| Reproductive cancer risk factors in women with myotonic dystrophy (DM): survey data from the US and UK DM registries C Higgs, JE Hilbert, L Wood, WB Martens, C Marini-Bettolo, N Nikolenko, ... Frontiers in Neurology 10, 1071, 2019 | 6 | 2019 |
| AMO-02 (tideglusib) for the treatment of congenital and childhood onset myotonic dystrophy type 1 J Horrigan, A McMorn, M Snape, N Nikolenko, T Gomes, H Lochmuller Neuromuscular Disorders 28, S14, 2018 | 6 | 2018 |
| Use of virtual reality game systems in rehabilitation of children with progressive muscular dystrophies (Игровая система виртуальной реальности в реабилитации детей с … N Nikolenko, OV Goncharova, SB Artemyeva, EE Achkasov, EB Litvinova Sports medicine: science and practice (Спортивная медицина: наука и практика), 2014 | 6 | 2014 |
| Dysregulation of GSK3β-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients V Grande, D Hathazi, E O’connor, T Marteau, U Schara-Schmidt, ... Journal of Neuromuscular Diseases 8 (4), 603-619, 2021 | 3 | 2021 |
| Change over time in ability to perform activities of daily living in myotonic dystrophy type 1 E Landfeldt, N Nikolenko, C Jimenez-Moreno, S Cumming, DG Monckton, ... Journal of Neurology 267, 3235-3242, 2020 | 3 | 2020 |
